-
Something wrong with this record ?
Altered Homeostatic Functions in Reactive Astrocytes and Their Potential as a Therapeutic Target After Brain Ischemic Injury
H. Pivonkova, M. Anderova,
Language English Country United Arab Emirates
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Astrocytes drug effects metabolism MeSH
- Gliosis drug therapy metabolism MeSH
- Homeostasis drug effects physiology MeSH
- Ion Channels antagonists & inhibitors metabolism MeSH
- Brain Ischemia drug therapy metabolism MeSH
- Humans MeSH
- Neurons drug effects metabolism MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Brain ischemic injury represents one of the greatest medical challenges for the aging population in developed countries, yet despite strong efforts, possibilities to treat ischemic injury still remain poor. Stroke, the most common type of brain ischemic injury in humans, is caused by brain artery occlusion, and represents a focal form of ischemia, which leads to neuronal loss in the ischemic core, and glial scar formation in the penumbral region around the core. Such glial scar mainly comprises reactive astrocytes, reactive NG2 glia and activated microglia. Reactive astrocytes display distinct features when compared to healthy astroglia, including changes in their morphology, metabolism, gene expression profiles, production of extracellular matrix proteins or proliferation rate. Similarly to astrocytes in the healthy nervous tissue, reactive astrocytes surrounding the glial scar strongly influence the activity of surviving neurons around the ischemic lesion. Bringing insight into pathophysiological functions of reactive astrocytes within the glial scar might thus open new possibilities for stroke treatment. Here, we summarize the properties of reactive astrocytes, with emphasis on the expression and function of ion channels, transporters and neurotransmitter receptors; all of which possess the ability to change the functional state of astrocytes, such as the membrane equilibrium potentials for different ions. This may have major effects on the functioning of surviving neurons, consequently leading to changes in neuronal excitability and progression of secondary pathologies, such as epilepsy. Moreover, we provide possible clues for therapy, based on functional modulation of astrocytic ion transporting mechanisms.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028776
- 003
- CZ-PrNML
- 005
- 20190819110441.0
- 007
- ta
- 008
- 190813s2017 ts f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1381612823666170710161858 $2 doi
- 035 __
- $a (PubMed)28699523
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ts
- 100 1_
- $a Pivonkova, Helena $u Department of Cellular Neurophysiology, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague. Czech Republic.
- 245 10
- $a Altered Homeostatic Functions in Reactive Astrocytes and Their Potential as a Therapeutic Target After Brain Ischemic Injury / $c H. Pivonkova, M. Anderova,
- 520 9_
- $a Brain ischemic injury represents one of the greatest medical challenges for the aging population in developed countries, yet despite strong efforts, possibilities to treat ischemic injury still remain poor. Stroke, the most common type of brain ischemic injury in humans, is caused by brain artery occlusion, and represents a focal form of ischemia, which leads to neuronal loss in the ischemic core, and glial scar formation in the penumbral region around the core. Such glial scar mainly comprises reactive astrocytes, reactive NG2 glia and activated microglia. Reactive astrocytes display distinct features when compared to healthy astroglia, including changes in their morphology, metabolism, gene expression profiles, production of extracellular matrix proteins or proliferation rate. Similarly to astrocytes in the healthy nervous tissue, reactive astrocytes surrounding the glial scar strongly influence the activity of surviving neurons around the ischemic lesion. Bringing insight into pathophysiological functions of reactive astrocytes within the glial scar might thus open new possibilities for stroke treatment. Here, we summarize the properties of reactive astrocytes, with emphasis on the expression and function of ion channels, transporters and neurotransmitter receptors; all of which possess the ability to change the functional state of astrocytes, such as the membrane equilibrium potentials for different ions. This may have major effects on the functioning of surviving neurons, consequently leading to changes in neuronal excitability and progression of secondary pathologies, such as epilepsy. Moreover, we provide possible clues for therapy, based on functional modulation of astrocytic ion transporting mechanisms.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a astrocyty $x účinky léků $x metabolismus $7 D001253
- 650 _2
- $a ischemie mozku $x farmakoterapie $x metabolismus $7 D002545
- 650 _2
- $a glióza $x farmakoterapie $x metabolismus $7 D005911
- 650 _2
- $a homeostáza $x účinky léků $x fyziologie $7 D006706
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a iontové kanály $x antagonisté a inhibitory $x metabolismus $7 D007473
- 650 _2
- $a neurony $x účinky léků $x metabolismus $7 D009474
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Anderova, Miroslava $u Department of Cellular Neurophysiology, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague. Czech Republic.
- 773 0_
- $w MED00007893 $t Current pharmaceutical design $x 1873-4286 $g Roč. 23, č. 33 (2017), s. 5056-5074
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28699523 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190819110715 $b ABA008
- 999 __
- $a ok $b bmc $g 1433925 $s 1067236
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 23 $c 33 $d 5056-5074 $e - $i 1873-4286 $m Current pharmaceutical design $n Curr Pharm Des $x MED00007893
- LZP __
- $a Pubmed-20190813